Evidence map›Paper›PMID 40832239›Full record

ArticlebioRxiv : the preprint server for biology2025

MutationAssessor in cBioPortal.

Yang Su, Xiang Li, Boris Reva, Yevgeniy Antipin, Nikolaus Schultz, Ino de Bruijn, Chris Sander

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang SuDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.
Xiang LiMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Boris RevaDepartments of Obstetrics/Gynecology & Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yevgeniy AntipinAlgoGenomics LLC, New York, NY, USA.
Nikolaus SchultzMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Ino de BruijnMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Chris SanderDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.

Funding

The cBioPortal for Cancer GenomicsU24CA274633 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Jianjiong Gao, CHRIS SANDER · 2022 to 2026
$7.4M
NCI NIH HHS U24 CA274633
6 · The paper itself

Abstract

MutationAssessor (MA) helps researchers evaluate the likely functional impact of somatic and germline mutations in cancer. It provides an evolution-based functional impact score (FIS) to classify mutations based on their likely effect on protein function. FIS scores are based on analysis of patterns of conservation in protein families (conserved residues) and subfamilies (specificity residues). In this new version (r4) we have (1) refined the combinatorial entropy analysis of conservation patterns, (2) recalculated full-length protein multiple sequence alignments covering a larger fraction of human proteins and making use of the explosive growth of protein sequence data, (3) compared predicted functional impact with the pathogenic-benign classification of sequence variants in curated knowledge bases, such as ClinVar, (4) observed the inverse relationship between predicted high functional impact and variant frequency in germline genome sequences and (5) explore the evaluation of switch-of-function mutational effects. Functional impact of ~4 million somatic amino-acid changing mutations across more than 320K human tumor samples are now available in the widely used cBioPortal for Cancer Genomics.

Identifiers

PMID40832239
PMCPMC12363874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.